In a significant development, ECO has received a positive opinion from the European Medicines Agency, recommending the approval of its ECOVAXXIN MS poultry vaccine. This is the first product in ECO’s innovative R&D pipeline and, as such, is a major validation of ECO’s approach and bodes well for future success, in our opinion. Marketing Authorisation is expected in Q1-CY26, with commercial launch in H2, in line if not slightly ahead of the most recent indicated timelines. Whilst not forecast changing in its own right initially, we expect the pipeline of new products to be a material growth and value driver for ECO in the medium term.
